Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
|Articles|July 14, 2022
Amy Paller, MD, Discusses Long-Term Safety and Efficacy of Ixekizumab in Kids
Author(s)Miranda Hester
Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.
Advertisement
Advertisement
Related to this article
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
JAK Inhibitors for Alopecia Areata: Selectivity and Pivotal Trial Efficacy
5